Macrocure Says Phase III Clinical Trial of CureXcell in Venous Leg Ulcers Not Expected to Meet Primary Endpoint.
August 20, 2015 at 04:26 AM EDT
Macrocure Ltd. (NASDAQ: MCUR) announced Wednesday, that a pre-specified, futility analysis conducted by the Data Safety Monitoring Board ...